阿帕替尼联合多西紫杉醇治疗小细胞肺癌的疗效及对血清proGRP、NSE、SIL-2R、VEGF的影响

Effect of Apatinib Combined with Docetaxel on Small Cell Lung Cancer and Serum ProGRP,NSE,SIL-2R,VEGF

目的探讨阿帕替尼联合多西紫杉醇治疗小细胞肺癌的疗效及对血清胃泌素释放肽前体(proGRP)、神经元特异性烯醇化酶(NSE)、可溶性白介素2受体(SIL-2R)及血管内皮生长因子(VEGF)的影响。方法选取唐山市人民医院2018年1月至2020年1月收治的小细胞肺癌患者150例。根据不同治疗方法将150例患者分为多西紫杉醇组、阿帕替尼组及联合组,每组50例。多西紫杉醇组接受多西紫杉醇标准方案治疗,阿帕替尼组接受阿帕替尼治疗,联合组接受阿帕替尼联合多西紫杉醇治疗,比较各组患者治疗前后proGRP、NSE、SIL-2R、VEGF、癌症疲乏量表(CFS)评分、生存质量调查表(QLQ-C30)评分变化及疗效情况。结果治疗前,各组患者proGRP、NSE、SIL-2R、VEGF、CFS评分、QLQ-C30评分比较差异均无统计学意义(P均>0.05);治疗后,各组proGRP、NSE、SIL-2R、VEGF、CFS评分均降低,QLQ-C30评分均升高(P均<0.05);联合组患者治疗后proGRP、NSE、SIL-2R、VEGF、CFS评分均低于多西紫杉醇组与阿帕替尼组,QLQ-C30评分高于多西紫杉醇组与阿帕替尼组(P均<0.05);联合组疾病控制率(84.00%)高于多西紫杉醇组(58.00%)和阿帕替尼组(62.00%),总生存时间(OS)及无进展生存时间(PFS)均长于多西紫杉醇组与阿帕替尼组(P均<0.05);各组患者术后临床不良反应差异无统计学意义(P>0.05)。结论阿帕替尼联合多西紫杉醇可有效降低小细胞肺癌患者血清proGRP、NSE、SIL-2R及VEGF等表达水平,提高患者生存质量,延长其生存时间。

Objective To investigate the effect of apatinib combined with docetaxel in the treatment of small cell lung cancer and its effect on serum gastrin releasing peptide precursor(proGRP),neuron specific enolase NSE),soluble interleukin-2 receptor(SIL-2R)and vascular endothelial growth factor(VEGF).Methods A total of 150 patients with small cell lung cancer from January 2018 to January 2020 were selected.According to different treatment methods,150 patients were divided into docetaxel group,apatinib group and combination group,with 50 cases in each group.The docetaxel group was treated with standard docetaxel regimen,the apatinib group was treated with apatinib,and the combination group was treated with apatinib combined with docetaxel.The changes of proGRP,NSE,SIL-2R,VEGF,cancer fatigue scale(CFS)score,quality of life questionnaire(QLQ-C30)score and curative effect before and after treatment were compared.Results Before treatment,there was no significant difference in proGRP,NSE,SIL-2R,VEGF,CFS and QLQ-C30 scores among the three groups(P>0.05);after treatment,proGRP,NSE,SIL-2R,VEGF and CFS scores were all decreased and QLQ-C30 scores were all increased in the three groups(P all<0.05);after treatment,proGRP,NSE,SIL-2R,VEGF and CFS scores in combination group were lower than those in docetaxel group and apatinib group,and QLQ-C30 scores were higher than those in docetaxel group and apatinib group(P all<0.05);and the disease control rate of combination group was(84.00%)higher than that of docetaxel group(58.00%)and apatinib group(62.00%).The total survival time(OS)and progression free survival time(PFS)were longer than that of docetaxel group and apatinib group(P all<0.05).There was no significant difference in clinical adverse reactions among the three groups(P>0.05).Conclusion Apatinib combined with docetaxel can effectively reduce the expression level of proGRP,NSE,SIL-2R and VEGF in serum of patients with small cell lung cancer,improve the quality of life,prolong survival time.